Skip to NavigationSkip to content

Cancer Drugs Fund

NICE and the CDF: Are they still up to scratch?

Published on 04/10/16 at 03:42pm

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to determine whether it is the fit-for-purpose appraisal system the industry needs.

The September issue of Pharmafocus is now live!

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial by looking at two of the most pressing issues in this field at the moment: transparency and cloud computing.

NICE says Afinitor and Imbruvica "may be removed" from Cancer Drugs Fund

NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs Fund as they are “not cost effective”.

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite its presence on the Cancer Drugs Fund (CDF) list.

Adcetris was indicated on the CDF for the treatment of refractory systemic anaplastic lymphoma, and the treatment of relapsed or refractory CD30+ Hodgkin’s lymphoma, but it had not yet been appraised by NICE.

Roche urges reform of Cancer Drugs Fund as NICE takes control

Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund (CDF) comes into effect today, July 29th 2016.

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat a form of blood cancer, a drug which was previously only available through the Cancer Drugs Fund (CDF).

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat lung cancer saying the therapy cost too much compared to combination chemotherapy. 

The appraisal committee also concluded that necitumumab did not meet the criteria to be considered for use in the Cancer Drugs Fund as it was not cost-effective and no clinical uncertainties could be addressed from further data collection. 

A win for Sanofi on Jevtana after NICE reverses guidance

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance.

The drug was originally rejected by NICE, and also taken off and then reinstated to the cancer drugs fund, amid concerns about the treatment’s cost-effectiveness compared with standard treatments.

Janssen slams NICE decision on Imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that it does not intend to recommend its Imbruvica (ibrutinib) to treat chronic lymphocytic leukaemia (CLL).

Eisai slams new Cancer Drugs Fund for delaying patient access

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the decision a failure that would further delay access to a number of new cancer treatments and set back cancer treatment in the country to its level prior to the Fund’s implementation in 2011.

The company, headquartered in Japan, said its thyroid cancer drug Lenvima (lenvatinib) has been “stuck in limbo” as a result of the consultation period on the reforms

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches